Overall, complete response rates for cycle 1 of treatment were 76.8% in the intravenous group and 84.1% in the oral treatment group, and no emesis rates were also similar (84.2% vs. 88.6%). However, the authors noted that the study was not powered to compare the efficacy of the two formulations.
Helsinn Healthcare sponsored the study and provided the drugs. Two authors were employees of the company, and four were consultants for the company. Two authors declared research support, advisory roles, and honoraria from pharmaceutical companies including Helsinn Healthcare. Three authors declared no conflicts of interest.
SOURCE: Schwartzberg L et al. Ann Oncol. 2018 May 10. doi: 10.1093/annonc/mdy169/4990798.